JO
MITO

John Overdeck’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

John Overdeck’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-13,314
Closed -$3K – 2981
2022
Q2 		$3K Buy
+13,314
New +$4.58K ﹤0.01% 2443
2020
Q2 		– Sell
-12,434
Closed -$15K – 3692
2020
Q1 		$15K Buy
+12,434
New +$27.6K ﹤0.01% 2982

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

John Overdeck's MITO Position: Q3 2022 in Review

John Overdeck sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q3 2022, closing a stake of 13,314 shares — an estimated $3K sold.

John Overdeck first reported a position in MITO in Q1 2020 and held it in 2 quarters. The position peaked at $15K in Q1 2020. 12 funds tracked by Wall St. Rank hold MITO as of Q3 2022.

  • John Overdeck reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q3 2022 after selling out during the quarter.
  • John Overdeck sold 13,314 Stealth BioTherapeutics Corp. ADS shares in Q3 2022, an estimated $3K.
  • John Overdeck first reported a position in Stealth BioTherapeutics Corp. ADS in Q1 2020 and held it in 2 quarters.
  • John Overdeck's Stealth BioTherapeutics Corp. ADS position peaked at $15K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q3 2022.

Based on Two Sigma Investments's 13F filing for Q3 2022, filed 14 Nov 2022.